White Paper:
Looking Ahead: Gastroenterology Clinical Trial Landscape in 2023

To meet the health needs of patients, the global GI drugs market is projected to grow at a compound annual growth rate (CAGR) of 6% from US$48.74 billion in 2021 to reach US$62.19 billion in 2025. Based on this, the market is valued at approximately US$54.8 billion in 2023. In 2020, North America held 48% of the global GI drugs market[3]. To bring new therapies to market, biopharma companies engage CROs for fast execution of high-quality clinical trials by leveraging their expertise in navigating the complex landscape of drug development and regulatory pathways.

This white paper will cover:

  • Growth in demand for gastroenterology CRO Services
  • Gastrointestinal Research Trends
  • Challenges and opportunities in GI trials: research waste, sex and gender bias, AI, and more